All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Latest updates from the phase III QuANTUM-First trial
During SOHO 2023, the AML Hub spoke to Harry Erba, Duke University, Durham, US. We asked, What are the latest updates from the phase III QuANTUM-First trial?
Quizartinib granted approval by the EC for patients with newly diagnosed FLT3-ITD-mutated AML
On November 9, 2023, quizartinib was approved by the EC for the treatment of adult patients with newly diagnosed FLT3-ITD-mutated AML in combination with...